Published in Clin Neuropharmacol on February 01, 1992
Quantitative analysis of the velocity related pathophysiology of spasticity and rigidity in the elbow flexors. J Neurol Neurosurg Psychiatry (2002) 1.71
Motor deficits and schizophrenia: the evidence from neuroleptic-naïve patients and populations at risk. J Psychiatry Neurosci (1999) 0.98
Effects of STN DBS on rigidity in Parkinson's disease. IEEE Trans Neural Syst Rehabil Eng (2007) 0.92
OroSTIFF: Face-referenced measurement of perioral stiffness in health and disease. J Biomech (2010) 0.84
Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. Biochem Biophys Res Commun (2000) 1.57
Cycad exposure and risk of dementia, MCI, and PDC in the Chamorro population of Guam. Neurology (2007) 1.48
Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 1.39
Apolipoprotein-epsilon4 and head trauma: Synergistic or additive risks? Neurology (1996) 1.02
Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease. Neurobiol Aging (2010) 0.89
Sensorimotor disinhibition in Parkinson's disease: effects of levodopa. Ann Neurol (1992) 0.87
A disturbance in the control of muscle force in neuroleptic-naive schizophrenic patients. Biol Psychiatry (1994) 0.85
Portable device for quantifying parkinsonian wrist rigidity. Mov Disord (1994) 0.82
Worsening of postural tremor in patients with levodopa-induced dyskinesia: a quantitative analysis. Clin Neuropharmacol (1993) 0.81
Extrapyramidal signs and cognitive abilities in Alzheimer's disease. Int J Geriatr Psychiatry (2001) 0.80
Neuromotor abnormalities and risk for psychosis in Alzheimer's disease. Neurology (2003) 0.78